The race to accelerate drug development continues, and China appears poised to have a great advantage in clinical trial speed. The good news is that it raising important questions about how the U.S. can remain competitive while maintaining rigorous patient safety and regulatory standards.
Read the full article in Bloomberg here: safety vs. quality vs. speed